The Biggest Week in Psychedelic Medicine Isn’t About Psychedelics. It’s About What Comes Next.
If it feels like we have been saying, “This is a historic moment for psychedelic medicine,” you are not wrong.
But this time, it truly is.
In the span of just a few days, two developments occurred that may help shape the future of this field for years to come.
In July 2026, the FDA finalized its guidance for clinical investigations involving psychedelic drugs, establishing formal recommendations for sponsors developing these therapies for medical conditions.
The guidance does not change how ketamine is practiced today. Instead, it outlines the regulatory considerations surrounding the development and study of potential future therapies involving psychedelic compounds.
For the first time, the FDA has finalized a dedicated framework addressing issues such as:
Eli Lilly announced an agreement to acquire AtaiBeckley, a clinical-stage biotechnology company developing rapid-acting neuroplastogens, in a transaction with potential consideration valued at up to $3.8 billion.
The company’s lead program, BPL-003, is an investigational intranasal formulation of mebufotenin benzoate, a synthetic form of 5-MeO-DMT being studied for treatment-resistant depression.
The agreement represents one of the pharmaceutical industry’s most significant commitments to date involving a company developing psychedelic-inspired mental health therapies.
One institution established the regulatory pathway.
Another committed billions of dollars to the future of the field.
That is not coincidence. It is confirmation.
Psychedelic medicine is no longer a fringe conversation. It is increasingly becoming part of mainstream healthcare, pharmaceutical development, clinical research, and regulatory planning.
But Here Is the Question We Should Really Be Asking
When providers see developments like these, the immediate question is often:
“Should I start offering psychedelic therapies?”
We believe there is a more important question:
Because the future is not simply about adding another treatment to a service menu.
It is about delivering a better model of care.
The Headlines Did Not Change Our Vision. They Validated It.
Long before psychedelic medicine began making front-page news, Brent Agin, MD, was studying the science of neuroplasticity and the growing body of research surrounding psychedelic compounds—including psilocybin, MDMA, and LSD.
Not because these therapies were commercially available.
Not because they were trending.
But because he believed they represented something much bigger: a shift toward treating the whole person rather than simply managing symptoms.
How can providers apply the principles of neuroplasticity, biological optimization, and whole-person care using the clinical tools available today?
At the same time, Brent Agin, MD, was building a clinical model around principles that could be implemented now.
For more than a decade, Priority You has combined functional medicine with ketamine therapy, helping patients address mental health challenges alongside the biological factors that may stand in the way of lasting improvement.
More than 6,000 patient experiences have reinforced one central principle:
Lasting transformation does not happen because of one therapy alone. It happens when providers create the biological and clinical conditions that allow healing to continue after treatment ends.
Healing Does Not Stop With the Brain
Neuroplasticity is incredibly powerful. But a patient’s brain does not exist in isolation.
| Hormone Deficiencies | Metabolic Dysfunction |
| Chronic Inflammation | Poor Sleep |
| Nutrient Depletion | Insulin Resistance |
| Mitochondrial Dysfunction | |
These factors are often part of the same patient story.
A patient may experience a meaningful breakthrough during ketamine therapy. But if the underlying physiology remains unaddressed, maintaining those improvements may become more difficult.
This is where functional medicine changes the conversation.
When brain health is supported alongside hormone optimization, metabolic health, peptide therapies, nutrition, lifestyle interventions, and personalized clinical care, providers are not simply responding to symptoms. They are helping create an environment where progress has a better opportunity to last.
Why We Created the Institute of Mindful Medicine
As psychedelic medicine continues to evolve, providers will need more than certification in a single therapy.
They will need a clinical framework.
That is why we created the Institute of Mindful Medicine.
Our training is designed to help providers understand how neuroplastic therapies fit into a comprehensive functional medicine model.
The model brings together brain health, hormones, peptides, metabolic function, nutrition, longevity medicine, patient experience, and whole-person care.
Because we believe the future belongs to providers who understand how these components work together—not as disconnected treatments, but as an integrated philosophy of healing.
Certification is only the beginning.
Confidence comes from understanding how to evaluate, implement, adapt, and support the treatment within the full context of the patient’s health.
The Future Is Already Taking Shape
This week’s headlines did not simply tell us where medicine may be going.
They confirmed that the movement is already underway.
The Future Is Not About Choosing One Side
At the Institute of Mindful Medicine, we do not believe the future of healthcare is about choosing between functional medicine and psychedelic medicine.
It is about bringing them together.
Neuroplastic interventions may open an important window for change. Functional medicine can help providers evaluate and support the biological systems that influence what happens during and after that window.
When providers understand both sides of the equation, the conversation changes from:
|
The Old Question
“Which treatment should I add?”
|
→ |
The Better Question
“What model of care will best support this patient?”
|
Final Thought
The FDA’s final guidance and Lilly’s multibillion-dollar acquisition agreement do not mean that every psychedelic therapy is ready for routine clinical use.
They do, however, demonstrate that the field has entered a more structured and consequential stage of development.
The providers who are best prepared for what comes next will not simply be those who learn how to administer a new therapy. They will be the providers who understand how to combine scientific curiosity with clinical responsibility, whole-person evaluation, ethical implementation, and long-term patient support.
Because the future is not just about new therapies. It is about building a new model of care.
Explore provider education, clinical support, implementation guidance, and integrated functional medicine training through MyPracticeConnect and the Institute of Mindful Medicine.
|
|
Written By
Shelley Junkin
Chief Operating Officer, MyPracticeConnect®
Shelley supports provider education, clinical implementation, and practice growth initiatives designed to help medical professionals confidently integrate functional and emerging therapies into patient care.
|
This article is provided for educational and informational purposes only and does not constitute medical, legal, business, or regulatory advice. Investigational psychedelic compounds, including psilocybin, MDMA, LSD, 5-MeO-DMT, mebufotenin, and related products, may not be approved by the FDA for routine clinical use. References to emerging research, investigational products, acquisitions, or regulatory guidance should not be interpreted as an endorsement, recommendation, or representation of safety or effectiveness. Ketamine use, prescribing, administration, patient selection, monitoring, marketing, and clinical protocols must comply with applicable federal and state laws, professional scope of practice, current evidence, informed consent requirements, and independent medical judgment.
- U.S. Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations. Final Level 1 Guidance. July 2026.
- U.S. Food and Drug Administration. FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order. April 24, 2026.
- Eli Lilly and Company. Lilly to Acquire AtaiBeckley to Advance Therapies for Treatment-Resistant Depression and Other Mental Health Conditions. July 16, 2026.
- AtaiBeckley. Clinical development information for BPL-003 and investigational rapid-acting neuroplastogen programs.
- National Institute of Mental Health. Educational resources regarding treatment-resistant depression, clinical research, and emerging mental health therapies.
- National Institutes of Health. Research resources related to neuroplasticity, synaptic signaling, ketamine, and psychedelic drug development.
- Institute of Mindful Medicine and MyPracticeConnect. Provider education materials related to ketamine therapy, functional medicine, clinical implementation, and whole-person care.